RxDoctor Payments Data

Rehana Qadir, MD

Internal Medicine · Davison, MINPI 1205092236

Payments from drug & device makers

$874in general payments, 2019–2025

Across 67 payments — averaging $13.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$238
  • Sanofi-aventis U.S. LLC$81
  • Merck$71
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$63
  • Pfizer$54
  • Johnson & Johnson$53
  • plus $313 from 14 others

What the payments were for

  • Food & beverage$874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$874 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$9,852
Medicare patients
54
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$55,632
EliquisApixaban68$53,800
MounjaroTirzepatide36$40,000
XareltoRivaroxaban14$22,411
JardianceEmpagliflozin16$22,267
JanuviaSitagliptin Phosphate15$18,977
TrulicityDulaglutide14$18,262
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,863
MyrbetriqMirabegron17$13,168
FarxigaDapagliflozin Propanediol12$9,488
Spiriva RespimatTiotropium Bromide12$7,126
SymbicortBudesonide/Formoterol Fumarate25$6,733
TradjentaLinagliptin21$6,117
Aripiprazole26$3,760
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp20$3,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$28$58,26250 claims
Novo NordiskOzempic$238$55,63240 claims
PfizerEliquis$54$53,80068 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$30$35,51149 claims
Johnson & JohnsonXarelto$53$22,41114 claims
MerckJanuvia$71$18,97715 claims
GSKTrelegy Ellipta$20$15,86315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Davison

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →